Amanote Research
Register
Sign In
Factors Associated With Dose Escalation of Fesoterodine for Treatment of Overactive Bladder in People >65 Years of Age: A Post Hoc Analysis of Data From the SOFIA Study
Neurourology and Urodynamics
- United States
doi 10.1002/nau.23814
Full Text
Open PDF
Abstract
Available in
full text
Categories
Neurology
Urology
Date
September 24, 2018
Authors
Unknown
Publisher
Wiley
Related search
Does Fesoterodine Have a Role in the Treatment of Poorly Managed Patients With Overactive Bladder?
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
OnabotulinumtoxinA for the Treatment of Overactive Bladder
Research and Reports in Urology
Urology
Botulinum Toxin a for the Treatment of Overactive Bladder
Toxins
Mutagenesis
Toxicology
Health
Factors Associated With Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)
Advances in Therapy
Medicine
Pharmacology
Mp65-16 Predictor Factors for Successful Treatment of Solifenacin in Patients With Overactive Bladder
Journal of Urology
Urology
Novel Use of Multivariate Joint Modelling to Identify Patient Level Factors Associated With Treatment Failure – Example of Botox Treatment for Patients With Overactive Bladder
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Sacral Neuromodulation for Treatment of Overactive Bladder: A Review
Revista de Medicina
Dealing With Complex Overactive Bladder Syndrome Patient Profiles With Focus on Fesoterodine: In or Out of the EAU Guidelines?
Research and Reports in Urology
Urology
Correction To: Imidafenacin for the Treatment of Overactive Bladder
Expert Opinion on Pharmacotherapy
Medicine
Pharmacology
